In a 2016 study published by the European Association for the Study of the Liver's Journal of Hepatology, researchers noted that, "HBsAg is essential to monitor the response to new therapeutic concepts."
"The widespread availability of quantitative HBsAg testing through Quest for use by hepatologists, gastroenterologists and other specialists will advance the care of HBV-infected patients," said Robert G. Gish, M.D., Medical Director, Hepatitis B Foundation and Principal, Robert G. Gish Consultants LLC. "The ability to reliably quantify surface antigen will enhance clinicians' ability to stage patient's disease state, provide prognostic information and help guide care with current antivirals and new therapies that are in the development pipeline."
Chronic hepatitis B infection is currently treated with antiviral therapies or interferon alpha (PEG-IFN). Unlike hepatitis C virus infection, in which direct acting antiviral drugs (DAAs) have high success rates, cure rates are lower for HBV due to the persistent nature of the virus and the low compliance rate with long-term therapies. Because viral load may be suppressed during treatment, it cannot be solely considered a sign of viral clearance; resolved chronic HBV is defined by clearance of HBsAg, according to the American Association for the Study of Liver Diseases (AASLD).
"An estimated 850,000 to 2.2 million persons in the U.S. are infected with chronic hepatitis B. While there are effective therapies that can functionally cure HBV infection, physicians in the U.S. have lacked tools that help predict individualized patient response to those treatments," said Rick L. Pesano, M.D., Ph.D., vice president, research and development, Quest Diagnostics. "With this new test capability, physicians can better develop tailored treatment plans and monitor HBV-infected patients to help prevent progression and better their chance for long-term immunity."
The hepatitis B virus can be transmitted by blood, semen, or other body fluid from a person infected with the virus. According to the Centers for Disease Control and Prevention (CDC), chronic Hepatitis B can lead to serious health issues, including cirrhosis or liver cancer.
Quest Diagnostics is a leader in hepatitis diagnostic information testing with services that include genotyping, viral load and antiviral resistance testing to aid diagnosis, treatment and monitoring. The company also collaborates with the CDC to identify trends in screening, diagnosis and treatment for viral hepatitis (hepatitis A, B, C and E) in the United States based on the national Quest Diagnostics Health Trends™ database of de-identified clinical hepatitis test data.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.
Kim Gorode, Quest Diagnostics (Media): 973-520-2800
Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quest-diagnostics-launches-nations-first-hepatitis-b-virus-quantitative-test-to-help-assess-response-to-antiviral-therapy-300392256.html
SOURCE Quest Diagnostics